10,584 Shares in CureVac (NASDAQ:CVAC) Acquired by Vontobel Holding Ltd.

Vontobel Holding Ltd. bought a new position in shares of CureVac (NASDAQ:CVAC) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 10,584 shares of the company’s stock, valued at approximately $45,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its holdings in CureVac by 95.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,738 shares of the company’s stock worth $39,000 after acquiring an additional 2,804 shares during the period. Swiss National Bank increased its holdings in CureVac by 1.8% during the 3rd quarter. Swiss National Bank now owns 221,406 shares of the company’s stock worth $1,462,000 after acquiring an additional 3,925 shares during the period. Pathstone Family Office LLC bought a new stake in CureVac during the 3rd quarter worth approximately $89,000. Deutsche Bank AG increased its holdings in CureVac by 5.1% during the 3rd quarter. Deutsche Bank AG now owns 72,510 shares of the company’s stock worth $495,000 after acquiring an additional 3,491 shares during the period. Finally, Federated Hermes Inc. increased its holdings in CureVac by 33.3% during the 3rd quarter. Federated Hermes Inc. now owns 40,000 shares of the company’s stock worth $273,000 after acquiring an additional 10,000 shares during the period. Institutional investors own 17.26% of the company’s stock.

Analyst Ratings Changes

Separately, Guggenheim reaffirmed a “neutral” rating on shares of CureVac in a report on Friday, April 5th.

CureVac Trading Down 3.5 %

Shares of NASDAQ:CVAC opened at $2.51 on Thursday. The company’s fifty day moving average price is $3.11 and its 200-day moving average price is $4.19. CureVac has a one year low of $2.34 and a one year high of $12.36. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.56 and a quick ratio of 3.41.

About CureVac

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.